Abstract
Purpose
To assess the effects of using a reduced dose of ganirelix with oral contraceptive pretreatment in a pilot study of COH using pure FSH for intrauterine insemination (IUI)
Methods
Patients received oral contraceptive (OC; 30 μg ethinyl estradiol/150 μg desogestrel) for 14–21 days and rFSH (50–225 IU/day SC) was started on day 4 after OC discontinuation. Ganirelix acetate (125 μg/day) was started with a lead follicle diameter of 14 mm.
Results
Of the 25 subjects who started oral contraceptives, one was cancelled due to an excessive response, and one subject was not included in the analysis because she did not receive ganirelix until the lead follicle was 18 mm. Median (range) starting FSH dose was 100 (50–225), cumulative rFSH dose was 1000 (675–2175) IU over 10 (9–17) days. Duration of ganirelix acetate treatment was 4.0 (2–5) days. Seven subjects (30.4%) delivered ten babies (three pregnancies were twins). There were no biochemical pregnancies or miscarriages. Of the 16 subjects with measurement of LH on the day of HCG administration, only one was under 0.5 mIU/ml (0.4), and only one was over 10 mIU/ml (17.7), and that subject delivered twins.
Conclusion
OC pretreatment afforded flexibility in scheduling while a reduced dose of ganirelix avoided excessive suppression of LH. The excellent results in this pilot study for IUI suggest this regimen could be further evaluated for scheduling IUI and IVF cycles.
This is a preview of subscription content, log in via an institution to check access.
References
Meldrum DR, Scott RT, Levy MJ, Alper MM, Noyes N. Oral contraceptive pretreatment in women undergoing controlled ovarian stimulation in ganirelix acetate cycles may, for a subset of patients, be associated with low serum luteinizing hormone levels, reduced ovarian response to gonadotropins and early pregnancy loss. Fertil Steril. 2008. In press.
Kolibianakis EM, Papanikolaou EG, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Hum Reprod. 2006;21:352–7. doi:10.1093/humrep/dei348.
Acevedo B, Sanchez M, Gomez JL, Cuadros J, Ricciarelli E, Hernandez ER. Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cycles. Fertil Steril. 2004;82:343–7. doi:10.1016/j.fertnstert.2004.03.020.
Bellver J, Albert C, Lambarta E, Pellicer A. Early pregnancy loss in women stimulated with gonadotropin-releasing hormone antagonist protocols according to oral contraceptive pretreatment. Fertil Steril. 2007;87:1098–101. doi:10.1016/j.fertnstert.2006.08.098.
Anonymous. The ganirelix dose-finding study group: A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (puregon). Hum Reprod. 1998;13:3023–31. doi:10.1093/humrep/13.11.3023.
Manzi DL, Dumez S, Scott LB, Nulsen JC. Selective use of leuprolide acetate in women undergoing superovulation with intrauterine insemination results in significant improvement in pregnancy outcome. Fertil Steril. 1995;63:866–73.
Allegra A, et al. GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial. Hum Reprod. 2007;22:101–8. doi:10.1093/humrep/del337.
Gomez-Palomares JL, Julia B, Acevedo-Martin B, Martinez-Burgos M, Hernandez ER, Ricciarelli E. Timing ovulation for intrauterine insemination with a GnRH antagonist. Hum Reprod. 2005;20:368–72. doi:10.1093/humrep/deh602.
Lambalk CB, Leader A, Olivennes F, et al. Treatment with GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicenter trial. Hum Reprod. 2006;21:632–9. doi:10.1093/humrep/dei386.
Crosignani PG, Somigliana E. Effect of GnRH antagonists in FSH mildly stimulated intrauterine insemination cycles: a multicentre randomized trial. Hum Reprod. 2007;22:500–5. doi:10.1093/humrep/del416.
Kosmas IP, Tatsioni A, Kolibianakis EM, et al. Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis. Fertil Steril. 2007;90(2):367–72.
Cedrin-Durnerin I, Massin N, Galey-Fontaine J, et al. Timing of FSH administration for ovarian stimulation in normo-ovulatory women: comparison of an early or a mid follicular phase initiation of a short-term treatment. Hum Reprod. 2006;21:2941–7. doi:10.1093/humrep/del259.
Author information
Authors and Affiliations
Corresponding author
Additional information
Capsule Supported by a research grant from Organon USA Inc., Roseland, NJ, USA
Rights and permissions
About this article
Cite this article
Meldrum, D.R., Cassidenti, D.L., Rosen, G.F. et al. Oral contraceptive pretreatment and half dose of ganirelix does not excessively suppress LH and may be an excellent choice for scheduling IUI cycles. J Assist Reprod Genet 25, 417–420 (2008). https://doi.org/10.1007/s10815-008-9244-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10815-008-9244-z